Clinical Research Directory
Browse clinical research sites, groups, and studies.
Prediction of Cognitive Properties of Memantine for Neurodegenerative Diseases
Sponsor: University Hospital, Lille
Summary
The early assessment of new drugs for Alzheimer's disease remains difficult because of the lack of predictive end-point. The use of a battery including different parameters could improve this early development of new drugs. Nevertheless, the interest of such a battery should previously be validated with the yet marketed AD drugs.
Official title: Effect of a 15-day Memantine Treatment on Biomarkers of AD in Healthy Volunteers
Key Details
Gender
MALE
Age Range
18 Years - 30 Years
Study Type
INTERVENTIONAL
Enrollment
30
Start Date
2016-09-14
Completion Date
2020-12-31
Last Updated
2026-05-05
Healthy Volunteers
Yes
Conditions
Interventions
Memantine
Memantine will be administered OS as of 10 mg- capsule one per day in the morning over 15 days.
Placebo
the placebo will be administered OS as of 10 mg- capsule one per day in the morning over 15 days.
Locations (3)
CHRU de Lille/ Centre d'investigation Clinique
Lille, France
CIC Marseille
Marseille, France
CIC Toulouse
Toulouse, France